Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578929 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
A Phase 3 study of Seasonal Allergic Rhinitis, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,388
- Enrollment target
- 1
- Study location
NCT00578929: Completed Phase 3 study of Seasonal Allergic Rhinitis, sponsored by Alcon Research.
NCT00578929 is a Phase 3 study of Seasonal Allergic Rhinitis that has completed, run by Alcon Research. The registered enrollment target is 2,388 participants, above the 519-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (360% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00578929, a Phase 3 study of Seasonal Allergic Rhinitis, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,388 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to demonstrate the superiority of test article nasal spray relative to vehicle nasal spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6 to 11 years with a history of seasonal allergic rhinitis.
Primary Outcome
Total Nasal Symptom Score comprised of scoring each of the following symptoms: runny nose, stuffy nose, itchy nose, and sneezing. Each symptom was scored as a 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The 4 individual symptom scores were then added together for a total nasal symptom score. The percent change from baseline was defined as the average of the morning and evening severity scores for the sum of the assessments of the 4 individual scores averaged across all days.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG Olopatadine Hydrochloride Nasal Spray 0.6%
Study Locations (1)
Illinois
- Kenilworth/IL - Kenilworth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,388 participants |
| Start Date | 2007-09 |
| Phase | Phase 3 |
What the finished NCT00578929 record still lists
NCT00578929 is an interventional study that assigns participants to a tested intervention. Its 2,388 participants enrollment target places it among the larger protocols in the corpus, above the 519-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target (360% higher).
The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT00578929 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00578929 about?
NCT00578929 is a clinical study titled "Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients". A study to demonstrate the superiority of test article nasal spray relative to vehicle nasal spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6 to 11 years with a history of seasonal allergic rhinitis.
What is the current status of trial NCT00578929?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,388 participants. The study started on 2007-09.
What conditions does trial NCT00578929 study?
This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.
What interventions are being tested in trial NCT00578929?
The interventions under investigation include: Vehicle (DRUG), Olopatadine Hydrochloride Nasal Spray 0.6% (DRUG).
Who is sponsoring clinical trial NCT00578929?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00578929 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00578929's enrollment target sits among peer trials
2,388 1st of 16 higher than 16 of 16 other Seasonal Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Seasonal Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
COMPLETED · Phase 3
-
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
COMPLETED · Phase 3
-
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
COMPLETED · Phase 3
-
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06747494 · 2,396 participants · NA
General vs Spinal in Total Joint Arthroplasty (TJA)
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
- NCT05285527 · 2,400 participants · NA
MiSight 1 Day Safety Post-Approval Study
- NCT05738330 · 2,400 participants · NA
Symptom Monitoring in Hemodialysis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia